
Anthem Biosciences Ltd Sees Bullish Momentum Shift Amid Technical Upgrades
2026-11-20 08:05:12Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by improvements in key technical indicators and a recent upgrade in its Mojo Grade from Buy to Hold, reflecting a nuanced market outlook as the stock approaches its 52-week high.
Read More
Anthem Biosciences Ltd is Rated Hold by MarketsMOJO
2026-11-17 10:10:50Anthem Biosciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 November 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 17 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreAnthem Biosciences Gains 2.41%: 3 Key Factors Driving the Week’s Momentum
2026-11-14 09:01:45Key Events This Week Nov 09: New 52-week and all-time high at Rs.989.15 and Rs.985.95 respectively Nov 11: Technical upgrade to bullish momentum amid positive indicators Nov 12-13: Mild price correction with declines of 2.02% and 0.22% Week Close: Rs.936.40, up 2.41% for the week Week Open Rs.914.35 <...
Read More
Broad-Based Technical Strength Lifts Anthem Biosciences Ltd to 52-Week High of Rs 989.15
2026-11-09 09:52:02With a sustained seven-day rally delivering a 17.33% gain, Anthem Biosciences Ltd surged to a fresh 52-week and all-time high of Rs 989.15 on 09 Nov 2026, outperforming its sector by 2.36% amid mixed market conditions.
Read MoreAnthem Biosciences Gains 10.37%: 3 Key Factors Driving the Weekly Rally
2026-11-07 10:00:39Key Events This Week 2 Nov: Stock opens at Rs.840.55, up 1.46% on strong market sentiment 4 Nov: Reports record quarterly profitability; stock surges 3.86% to Rs.887.45 5 Nov: Downgrade to Hold and quality grade lowered; stock still gains 2.94% 6 Nov: Week closes at Rs.914.35, up 0.09% amid cautious optimism Week OpenRs.828.45 <div class="stat-lab...
Read More
Anthem Biosciences Ltd Reports Strong Quarterly Turnaround with Record Profitability
2026-11-04 11:00:40Anthem Biosciences Ltd has delivered a remarkable financial turnaround in the quarter ended September 2026, reversing a negative trend to post its highest-ever profitability metrics. The mid-cap pharmaceutical and biotechnology company’s latest results highlight robust revenue growth, margin expansion, and improved earnings per share, signalling renewed investor confidence and a positive outlook for the sector.
Read More
Anthem Biosciences Ltd is Rated Hold
2026-10-23 10:10:03Anthem Biosciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Anthem Biosciences Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-09-29 08:08:17Anthem Biosciences Ltd has experienced a notable shift in its technical momentum, transitioning from a bullish to a mildly bullish stance as of late September 2026. Despite a recent dip in price, the stock’s underlying technical indicators present a complex picture, reflecting both resilience and caution within the Pharmaceuticals & Biotechnology sector.
Read MoreAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript
06-Nov-2026 | Source : BSETranscript of Q2 & H1 FY27 Earnings Conference Call
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
05-Nov-2026 | Source : BSEIntimation of Schedule of Analyst Meet/Institutional Meet
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
05-Nov-2026 | Source : BSEAudio recording of Earnings Call for the quarter ended September 30 2026.
Corporate Actions
No Upcoming Board Meetings
Anthem Biosciences Ltd has declared 100% dividend, ex-date: 25 Jun 26
No Splits history available
No Bonus history available
No Rights history available
